.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
Browse the portfolio.
What you can license, right now. Four asset families for the V1 launch, each a SenseReady™ standard. More assets in development across our sensing categories.
.avif)
.svg){kind=small}
.avif)
.avif)
Not an in-buffer binder. A finished aptamer asset.
Performance engineered in
Designed against multiple application-critical requirements, not binding alone.
Developed upfront
PentaBind self-funds design and validation before licensing.
Licensed with evidence
Selected partners license a defined aptamer asset supported by a characterised performance profile and application-relevant matrix data.
Multifunctional by design. Ready for continuous sensing.
SenseReady™ aptamers are engineered and benchmarked across the multiple capabilities continuous sensors demand, from affinity and specificity to biofluid compatibility, stability and reversible switching.
Binding affinity
Binding strength engineered for target concentrations in the intended biofluid.
Selectivity
Discriminates the target from structurally similar molecules and other potential interferents.
Biofluid compatibility
Maintains functional performance in relevant matrices such as ISF, sweat, saliva or serum.
Functional stability
Retains its structure and performance under intended operating and storage conditions.
Reversible binding
Repeatedly binds and releases the target, enabling dynamic rather than single-point measurement.
Selected characteristics from the full SenseReady™ performance profile.
.avif)
Beyond Binding
Conventional aptamer programmes typically conclude once target binding has been demonstrated. SenseReady™ closes the gap between binder discovery and device integration.
What has been demonstrated
Where it has been tested
How it has been developed
Development stage
Where the partner begins
How it is accessed
In-buffer Binder
.svg)
SenseReady™ Aptamer
Is your aptamer commercially viable?
Binding alone is not enough. An application-ready aptamer must perform across three levels of validation:
- Affinity matched to the target range
- Selectivity against close analogues
- Reversible binding and switching
- Matrix compatibility
- Functional stability
- Relevant operating conditions
- Detectable signal response
- Repeatability and reproducibility
- Continuous cycling performance
.svg)
Teams have pursued aptamer-based sensing for more than a decade. What makes your approach more likely to succeed?
The multi-characteristic platform behind SenseReady™
Built on five years of proprietary sequence–function data, the platform combines predictive design with iterative wet-lab validation. It doesn’t simply accelerate conventional discovery, it engineers aptamers against multiple application requirements simultaneously.
Proprietary, multi-characteristic sequence–function measurements.
.svg)
Each cycle expands and strengthens the proprietary training dataset.
Experimental results guide optimisation and the next design cycle.
.svg)
AI learns how sequence and structure influence molecular performance.
.svg)
New sequences are designed against a multi-characteristic target profile.
.svg)
Candidates are tested against application-relevant performance criteria.
.svg)
300×
more high-affinity hits
~22 days
to first confirmed binders
~75–100 days
to application-ready assets
What our customers say
"We're always looking for ways to accelerate our progress. Another major diagnostics company recommended we contact you"
.png)
"This should make our life extremely easy. What we'll basically be doing is substituting our commercial aptamers with your aptamers"
"Your approach takes a huge amount of complexity off our plate. It makes our life much easier."
The practical path to a license.
Select a target
Explore the portfolio or nominate a target for the SenseReady™ roadmap.
Apply for licensing
We assess each partner’s commercial, technical and regulatory plan, including reimbursement where applicable.
Reserve and license an asset
Selected partners reserve an asset within the target family and license a defined aptamer.
Built by someone who's sat in your seat.
Every SenseReady™ asset is already developed, you pay licence fees only after the asset has been validated against its agreed specification.
- Founder background in diagnostics, sourced aptamers that failed outside the lab
- PentaBind built to solve that exact problem for the industry
- Assets designed, validated and delivered before any conversation starts
